Anaptysbio, inc (ANAB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Revenue from Contract with Customer, Excluding Assessed Tax

8,000

5,000

10,000

16,684

17,571

Operating expenses:
Research and development

99,338

56,196

29,443

15,419

17,304

General and administrative

16,094

15,526

9,338

4,290

3,589

Total operating expenses

115,432

71,722

38,781

19,709

20,893

Loss from operations

-107,432

-66,722

-28,781

-3,025

-3,322

Other income (expense), net:
Interest expense

1,041

1,652

1,775

458

460

Change in fair value of liability for preferred stock warrants

0

0

1,366

756

1,277

Interest income

10,984

6,685

1,623

127

18

Other income, net

1

-159

229

-147

-225

Total other income (expense), net

9,944

4,874

-1,289

-1,234

-1,944

Loss before income taxes

-97,488

-61,848

-30,070

-4,259

-5,266

Provision for income taxes

-152

-192

0

0

139

Net loss

-97,336

-61,656

-30,070

-4,259

-5,405

Other comprehensive income (loss):
Income tax expense related to other comprehensive income

-

-

-

0

-

Unrealized income on available for sale securities, net of tax of $0 and $115, respectively

561

203

-426

0

0

Other comprehensive income (loss), net of tax

-

-

-

0

0

Comprehensive loss

-96,775

-61,453

-30,496

-4,259

-5,405

Net loss per common share:
Basic and diluted (in dollars per share)

-3.60

-2.50

-1.52

-1.62

-2.12

Weighted-average number of shares outstanding:
Basic and diluted (in shares)

27,059

24,673

19,782

2,637

2,551